Problems in prescribing malaria chemoprophylaxis for travelers

Fundamental and Clinical Pharmacology

Volumn 17, Issue 2, 2003, Pages 161-169

  Dupouy Camet, Jean ^a   Yera, Hélène ^a   Tourte Schaeffer, Claudine ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Atovaquone; Chloroquine; Doxycycline; Malaria; Mefloquine; Proguanil; Prophylaxis; Traveler

Indexed keywords

ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DOXYCYCLINE; MEFLOQUINE; PROGUANIL;

ANTIMALARIAL ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; DEPRESSION; EXPOSURE; GASTROINTESTINAL SYMPTOM; GENETIC HETEROGENEITY; HALLUCINATION; HUMAN; INSECT BITE; MALARIA; MENTAL DISEASE; MOUTH ULCER; NAUSEA; PANIC; PATIENT COMPLIANCE; PHOTOSENSITIZATION; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; STRAIN DIFFERENCE; TRAVEL; VAGINA CANDIDIASIS; VERTIGO;

ANIMALS; ANTIMALARIALS; ATOVAQUONE; CHILD; CHLOROGUANIDE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE; ENDEMIC DISEASES; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INSECT BITES AND STINGS; MALARIA, FALCIPARUM; MOSQUITO CONTROL; NAPHTHOQUINONES; PATIENT COMPLIANCE; PREGNANCY; TRAVEL;

EID: 0037397986     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00166.x     Document Type: Article

References (46)

1. WHO. Malaria. 1982-1997. Weekly Epidemiol. Rec. (1999) 74 265-272.
2. Danis M., Legros F., Thellier M., Caumes E. Current data on malaria in metropolitan France. Med. Trop. (2002) 62 214-218.
3. Bradley D.J., Bannister B. Guidelines for malaria prevention in travellers from the United Kingdom for 2001. Commun. Dis. Public Health (2001) 4 84-101.
4. Centers for Disease Control and Prevention. Malaria surveillance-United states- 1995. Morb. Mortal. Wkly. Rep. (1999) 48 1-21C.
5. Dorsey G., Gandhi M., Oyugi J.H., Rosenthal P.J. Difficulties in the prevention, diagnosis and treatment of imported malaria. Arch. Intern. Med. (2000) 160 2505-2510.
6. Muentener P., Schlagenhauf P., Steffen R. Imported malaria (1985-95): trends and perspectives. Bull. of the World Health Org. (1999) 77 560-566.
7. Schwartz E., Sadetzki S., Murad H., Raveh D. Age as a risk factor for severe Plasmodium falciparum malaria in nonimmune patients. Clin. Inf. Dis. (2001) 33 1774-1777.
8. Legros F., Danis M. Surveillance of malaria in European Union countries. Eurosurveillance (1998) 3 45-47.
9. Sabatinelli G., Ejov M., Joergensen P. Malaria in the WHO European region (1971-1999). Eurosurveillance (2001) 6 61-65.
10. Banerjee D., Stanley P.J. Malaria chemoprophylaxis in UK general practitioners traveling to South Asia. J. Travel Med. (2001) 8 173-175.
11. Anonymous. Recommandations sanitaires pour les voyageurs 2002. Bull. Epidemiol. Hebdo. (2002) 24 111-117.
12. WHO. The use of antimalaria drugs. Report of an informal consultation. WHO-RBM 2001. (available at http://mosquito.who.int)
13. Carnevale P. Protection des voyageurs contre les piqûres d'arthropodes vecteurs. Bull. Soc. Pathol. Exot. (1998) 91 474-485.
14. Mc Gready R., Hamilton K.A., Simpson J.A. et al. Safety of the insect repellent N, N-diethyl-M-toluamide (DEET) in pregnancy. Am. J. Trop. Med. Hyg. (2001) 65 285-289.
15. Briassoulis G., Narlioglou M., Hatzis T. Toxic encephalopathy associated with use of DEET insect repellents: a case analysis of its toxicity in children. Hum. Exp. Toxicol. (2001) 20 8-14.
16. Fischer P.R., Bialek R. Prevention of malaria in children. Clin. Inf. Dis. (2002) 34 493-498.
17. Fradin M., Day J.F. Comparative efficacy of insect repellents against mosquito bites. N. Engl. J. Med. (2002) 347 13-18.
18. Izri A., Konate L., Dieng Y. et al. Efficacité de l'association DEET (20%) et EHD (15%) contre les piqûres de moustiques. Résultats d'une étude réalisée au Sénégal. Bull. Soc. Pathol. Exot. (2001) 94 280-283.
19. Amalraj D.D., Sivagnaname N., Boopathidoss P.S., Das P.K. Bioefficacy of mosquito mat, coil and dispenser formulations containing allethrin group of synthetic pyrethroids against mosquito vectors. J. Commun. Dis. (1996) 28 85-93.
20. Subramanian D., Moise K.J. Jr. White A.C. Jr. Imported malaria in pregnancy: report of four cases and review of management. Clin. Infect. Dis. (1992) 15 408-413.
21. Vanhauwere B., Maradit H., Kerr L. Post-marketing surveillance of prophylactic mefloquine use in pregnancy. Am. J. Trop. Med. Hyg. (1998) 58 17-21.
22. Anonymous. Pregnancy and mefloquine prevention of malaria. Prescrire Int (2000) 9 180-181.
23. Conlon C.P. The immunocompromised traveller. Br. Med. Bull. (1993) 49 412-422.
24. Chandramohan D., Greenwood B.M. Is there an interaction between human immunodeficiency virus and Plasmodium falciparum? Int. J. Epidemiol. (1998) 27 296-301.
25. Whitworth J., Morgan D., Quigley M. et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episode in adults in rural Uganda: a cohort study. Lancet (2000) 356 1051-1056.
26. Castelli F., Patroni A. The human immunodeficiency virus-infected traveler. Clin. Infect. Dis. (2000) 31 1403-1408.
27. Schippers E.F., Hugen P.W., den Hartigh J. et al. No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients. AIDS. (2000) 14 2794-2795.
28. Behrens R.H., Taylor R.B., Low A.S., Warburton B., Pryce D. Traveller's diarrhoea: a controlled study of its effect on chloroquine and proguanil absorption. Trans. R. Soc. Trop. Med. Hyg. (1994) 88 86-88.
29. Adebayo R.A., Sofowora G.G., Onayemi O., Udoh S.J., Ajayi A.A. Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine. Br. J. Clin. Pharmacol. (1997) 44 157-161.
30. Ademowo O.G., Sodeinde O., Walker O. The disposition of chloroquine and its main metabolite desethylchloroquine in volunteers with and without chloroquine-induced pruritus: evidence for decreased chloroquine metabolism in volunteers with pruritus. Clin. Pharmacol. Ther. (2000) 67 237-241.
31. Epstein K. The Lariam files. Washington Post, 10 October 2000.
32. Barrett P.J., Emmins P.D., Clarke P.D., Bradley D.J. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ (1996) 313 525-528.
33. Croft A., Garner P. Mefloquine to prevent malaria: a systematic review of trials. BMJ (1997) 315 1412-1416.
34. Hogh B., Larke P.D., Camus D. et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune travellers: a randomised, double blind study. Malarone international study team. Lancet (2001) 357 1289-1290.
35. Overbosch D., Schilthuis H., Bienzle U. et al. Malarone international study Team. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non immune travelers: results from a randomized, double blind study. Clin. Inf. Dis. (2001) 33 1015-1021.
36. Held T.K., Weinke T., Mansmann U., Trautmann M., Pohle H.D. Malaria prophylaxis: identifying risk groups for non-compliance. Q. J. Med. (1994) 87 17-22.
37. Gyorkos T.W., Svenson J.E., MacLean J.D. Mohamed N., Remondin D.H., Franco E.D. Compliance with antimalaria chemoprophylaxis and the subsequent development of malaria: a matched case-control study. Am. J. Trop. Med. Hyg. (1995) 53 511-517.
38. Carme B., Peguet C., Nevez G. Prophylaxie du paludisme: tolérance et compliance de la méfloquine et de l'association proguanil-chloroquine chez des touristes français. Bull. Soc. Path. Exot. (1997) 90 273-276.
39. Petersen E., Ronne T., Ronn A., Bygbjerg I., Larsen J. SO. Reported side-effects to chloroquine, chloroquine plus proguanil, and mefloquine as chemoprophylaxis against malaria in Danish travellers. J. Travel. Med. (2000) 7 79-84.
40. Croft A.M., Herxheimer A. Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement? BMC Public Health (2002) 25 2-6.
41. Schwartz E., Regev-Yochay G. Primaquine as prophylaxis for malaria for non immune travelers: a comparison with mefloquine and doxycycline. Clin. Inf. Dis. (1999) 29 1502-1506.
42. Taylor W.R., Richie T.L., Fryauff D.J. et al. Malaria prophylaxis using azythromycin: a double blind, placebo controlled study in Irian Jaya. Indonesia. Clin. Infect. Dis. (1999) 28 74-81.
43. Kain K.C., Shanks G.D., Keystone J.S. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. Clin. Inf. Dis. (2001) 33 226-234.
44. Fivelman Q.L., Butcher G.A., Adagu I.S., Warhurst D.C., Pasvol G. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar, J. (2002) 1 1-4 (available from http://www.malariajournal.com:content/1/1/1).
45. Shanks G.D., Kain K.C., Keystone J.S. Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. Clin. Inf. Dis. (2001) 33 381-385.
46. Lell B., Faucher J.F., Missinou M.A. et al. Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet (2000) 355 2041-2045.